Kornimate/medical-research-clean huggingface dataset:
measurement of patient reported outcomes in renal transplant patients with and without gastrointestinal (gi) symptoms

Conditions: Kidney Transplantation; GI Symptoms Severity

Summary: this study will access the gi complaints on patients reported outcomes and to determine the improvement in quality of life in patients.


Eligibility criteria:
inclusion criteria: * patient received kidney transplant at least 1 month prior to study with mmf as a part of the treatment for at least 2 weeks. * eligible to convert to myfortic because of gi complaints or not currently experiencing gi complaints and stable on current immunosuppressive regimen. * at least 18 years of age; * willing to provide written informed consent; and * able to meet all study requirements including completing paper questionnaires and completing two study visits. exclusion criteria: * gi symptoms assumed or known not be caused by mpa therapy and have recent acute rejection at least 1 week prior to the study. * breast-feeding or pregnant woman. * patients with psychiatric illness. * underlying acute medical intervention or hospitalization * receiving investigational drug within 30days prior to study.

Keywords: kidney transplantation mycophenolate sodium ec-mps health related quality of life gi symptoms immunosuppressants hrql pgwb giqli
efficacy of collagen, propolis plus quercetin (proqutin®), bacillus coagulans, hyaluronic acid and chondroitin sulphate and d-mannose to avoid symptoms and prevents recurrence in women with recurrent urinary tract infections

Conditions: Urinary Tract Infection (Diagnosis)

Summary: the aim of this study is to evaluate whether a dietary supplement based on d-mannose, collagen, hyaluronic acid, chondroitin sulphate, enhanced by the properties of quercetin plus propolis (proqutin ®) and bacillus coagulans, eventually associated with antimicrobial prophylaxis, could be effective in preventing recurrent utis and improving related quality of life.


Eligibility criteria:
inclusion criteria: * a history of rutis (defined by eau guidelines as a frequency of at least three utis per year, or two utis in the past six months in the last 12 months, confirmed by positive urine cultures * not undergone any previous treatment for their condition. exclusion criteria: * age under or over limit * concurrent antimicrobial treatment * any ongoing treatment that could influence study outcomes, * congenital or post-surgical urinary tract anomalies * immunodeficiency or hiv infection * ongoing pregnancy.
memantine for the treatment of cognitive dysfunction and negative symptoms in patients with chronic schizophrenia

Conditions: Chronic Schizophrenia

Summary: the purpose of this study is to evaluate the efficacy and safety of 24 weeks memantine add-on treatment to risperidone for the treatment of negative symptomatology and cognitive impairment in patients with chronic schizophrenia.

this study examines the efficacy and safety of 24 weeks memantine add-on treatment to risperidone for the treatment of negative symptomatology and cognitive impairment in patients with chronic schizophrenia. the trail was double-blind, prospective, randomized, placebo-controlled, parallel-group and consisting of a 'placebo-run-in' period, treatment, and follow-up periods. study personnel and participants were blinded to group assignment. in the 'run-in' period, patients received lorazepam for the treatment of anxiety and tension states for two weeks before starting antipsychotic therapy. after the 'run-in' period treatment, patients began receiving antipsychotic therapy with risperidon with continuous concomitant administration of a 24 weeks memantine, 20 mg/d, or placebo. adherence was assessed at each clinic visit by pill count. in cases of anxiety and tension states, an experienced psychiatrist decided whether patients should receive lorazepam, 5 mg/d, as rescue medication in addition to the study medication (memantine or placebo), to which the patients remained blinded. in cases of pseudo parkinsonism patients were allowed to receive biperiden, up to 8 mg/d, and for the treatment of patients suffering from sleep disorders zopiclon (15 mg/d) was allowed. the consumption of alcohol and drugs were not allowed during the trial. in both study parts, psychiatric assessments were performed at baseline as well as after 2; 4; 6; 12 and 24 weeks after treatment (that is, during the follow-up period). the neuropsychological examination was performed at baseline, and after 6 and 24 weeks. psychiatric changes, adverse events, laboratory values, dose adjustments of the antipsychotic therapy, and possible pharmacologic adverse effects were systematically monitored throughout the study.

Eligibility criteria:
inclusion criteria: * diagnosis of schizophrenia (dsm-iv) * age 18 to 40 * stable negative syndrome (panss negative score \> 20) * at least one previous schizophrenic episode * informed consent * subjects must be considered by the investigator to be compliant with investigations and appointments * subjects must have an educational level and a degree of understanding such that they can meaningfully communicate with the investigator exclusion criteria: * axis i disorder other than schizophrenia within 12 months, e.g. schizoaffective disorder * severe positive symptomatology (panns positive score \> panns negative score) * dependency on alcohol or addictive drugs within 6 months of the baseline evaluation * contraindication of risperidone * significant neurological, cardiovascular, hepatic, renal, metabolic, or other medical diseases or any clinically relevant abnormalities in laboratory tests

Keywords: memantine negative syndrome schizophrenia cognitive impairment
st. john's wort and kava in the treatment of major depressive disorder with comorbid anxiety

Conditions: Depressive Disorder, Major; Anxiety Disorders

Summary: sjw has the greatest evidence of herbal medicine efficacy in treating mdd. in treating anxiety, kava has the greatest evidence of efficacy. as comorbidity of mdd and anxiety commonly occurs, it is conceivable that a combination of an established antidepressant agent such as sjw and an established anxiolytic agent such as kava may effectively treat mdd presenting with comorbid anxiety. it is possible that a beneficial synergistic effect may also occur between sjw and kava, improving the treatment outcomes in mdd with comorbid anxiety, than by the individual substances alone. determination of this is not addressed in this study due to limitations of time and resources. the determination of the strength of the sjw-kava combination will be ascertained by comparing similar trials using sjw and kava mono-therapy in addressing mdd and gad. the hypothesis is that a combination of sjw and kava will reduce mdd occurring with comorbid anxiety more than placebo.


Eligibility criteria:
inclusion criteria: * any person male or female aged 18-65 presenting with a diagnosis of unipolar depression confirmed by cidi auto (quantified by bdi) and an anxiety score on the dass of 8 or above i.e. the mean (quantified also by bai) exclusion criteria: * psychotic/ bipolar illness * current or \< 6 month significant suicidal ideation * diagnosed hepato-biliary disease/inflammation * current or \< 6 month substance abuse disorder including alcohol * current or \< 12 month use of kava, st. john's wort, * current or \< 1 month of synthetic antidepressants or benzodiazepines * previous reaction to kava or st. john's wort * medications that maybe pharmacokinetically altered via st. john's wort including: * amitriptyline anti-coagulants e.g. phenprocoumon, warfarin, * anti-fugals e.g. voriconazole, * anti-histamines e.g. fexofenadine, * benzodiazepines e.g. alprazolam, * chemotherapeutics e.g. irinotecan, digoxin, hiv medication (anti-retrovirals), \* immunosuppressants e.g. cyclosporine, methadone, ocp, * statins e.g. simvastatin, warfarin (henderson 2002; izzo 2004). * however this interactions are based on case studies and theoretical interactions and are regarded to be induced by hyperforin (a constituent of st. john's wort); low or non-standardised hyperforin preparations are regarded to not induce drug interactions as little induction of p-glycoprotein and cyp p450 enzymes occurs (madabushi et al. 2006). although in vitro studies have confirmed that kava and the isolated kavalactones modulate certain cyp 450 enzymes, no documented evidence of human kava-drug pharmacokinetic interactions exists (mathews, etheridge \& black 2002; singh 2005) * seeing a psychologist or counsellor currently or in the previous month. * non-english speakers. * pregnancy

Keywords: plant, medicine psychiatry major depressive disorder anxiety major depressive disorder with comorbid anxiety
anxiety/depression, sleep and alcohol in elderly anxiety/depression, sleep disturbances and alcohol use disorder in elderly with cognitive complaints

Conditions: Anxiety State; Sleep Disturbance; Alcohol Abuse; Aging; Dementia

Summary: the goal of mem-asa is to investigate the prevalence of anxiety/depression, sleep disturbances and alcohol use disorder in elderly with cognitive complaints. in memory clinics of normandy (france), all patients aged over 50 year-old are systematically questioned about anxiety, depression, sleep quality and alcohol use disorder. they also perform a neuropsychological assessment. questionnaires are given to the patient and his/her caregiver to be filled in at home. levels of anxiety/depression, sleep quality and alcohol consumption are related to neuropsychological performance, diagnosis and responses to the questionaires.


Eligibility criteria:
inclusion criteria: * to have cognitive complaints * to have french as native language * not to be opposed to be included * to be affiliated to the social security exclusion criteria: -to be under tutorship or curatorship
early assessment of respiratory function, inflammation and bronchial reshuffle among newborns screened for cystic fibrosis

Conditions: Cystic Fibrosis

Summary: the main objective of this study is to show that there is a concordance between lung disease at 13 months and the existing 9 weeks in newborn babies with cystic fibrosis asymptomatically. this will identify at the first examination at 8 weeks, newborns who have the most impaired lung function at 13 months. to meet this objective an assessment of their lung function at 9 weeks and 1 month will be performed in newborns diagnosed with cystic fibrosis.


Eligibility criteria:
inclusion criteria : * infant aged 11 weeks exclusion criteria : * gestational age lower than 35 weeks of gestation, * background invasive mechanical ventilation in positive pressure * documented -obstructive sleep apnea, heart defect, neuromuscular disease
clinical, pharmacological and molecular effects of iv and oral acetaminophen in adults with asah

Conditions: Subarachnoid Hemorrhage; Stroke

Summary: this study compares the bioavailability of iv and po acetaminophen in both blood and the cerebrospinal fluid (csf) of patients following subarachnoid hemorrhage. the study will also compare the temperature and levels of inflammatory cytokines in both blood and csf of patients treated with iv and po acetaminophen.

in individuals diagnosed with subarachnoid hemorrhage (sah), fevers have been shown to have detrimental micro and macroscopic effects on the brain that can ultimately cause secondary brain injury. the anti-pyretic effects of oral acetaminophen have been studied in critically ill patients but no study has been able to compare these effects to the iv form of acetaminophen also known as ofirmev. the investigators wish to explore the notion that iv acetaminophen will be more effective than enteral acetaminophen in reducing the incidence of non-infectious fevers in critically ill patients. in addition, the investigators propose to study the levels of inflammatory cytokines after administration of iv or enteral acetaminophen, as well as, determine the incidence of vasospasm in sah patients treated with iv acetaminophen. currently, external ventricular drain (evd) placement is the "standard of care" in patients who present with sah and altered mental status/coma. the presence of an evd allows for continuous sampling and removal of cerebral spinal fluid (csf) as necessary to alleviate dangerous elevations in intracranial pressure. this clinical scenario allows for a unique, continuous outlet to access the csf, without placing patients at risk, and without further invasive procedures (i.e. repeated spinal taps). these samples of csf can be assayed for levels of acetaminophen, as well as inflammatory markers of fever which include interleukin-1 (il-1), interleukin-6 (il-6), and thromboxane-2 (txa-2), in patients selected to be given enteral or iv acetaminophen.

Eligibility criteria:
inclusion criteria: * diagnosis of subarachnoid hemorrhage (must be confirmed by ct, ct angiography, lumbar puncture, or mri). * fisher grade between 1-3 (subarachnoid blood without signs of intraventricular hemorrhage or parenchymal extension). * placement of an external ventricular drain. * adults aged 18-100 years. exclusion criteria: * anyone under the age of 18 or over the age of 100. * adult patients with subarachnoid hemorrhage with interventricular hemorrhage or parenchymal extension (fisher grade 4). * contraindication to acetaminophen such as a known hypersensitivity, severe hepatic impairment, or severe active liver disease. * severe renal impairment (creatinine clearance ≤ 30 ml/min).

Keywords: acetaminophen interleukin-6 interleukin-1 thromboxane a2
thoracic fluid content during hypervolemic hemodilution

Conditions: Pulmonary Edema

Summary: thoracic fluid content (tfc) is one of the many variables measured by the icon electrical cardiometry (ec) device (osypka medical). the icon device is often called "thoracic electrical bio-impedance" that based on measuring the changes in total resistance of the thorax to electric current and is considered a numerical measure of total (intravascular and extravascular) thoracic fluid. although tfc is a measure of both extra and intra-vascular thoracic fluid, it provides an estimate of the increase in intrathoracic fluids such as to facilitate the risk of pulmonary edema. although many studies were done on the ability of tfc to detect pulmonary edema in preeclampsia, ards, heart failure, weaning from mechanical ventilation and during fluid management in prolonged surgery , yet, there is no study before was done on the use of tfc as a guide for fluid therapy during hypervolemic hemodilution in major obstetric surgery in patients with placenta accreta as one of the most common etiologies of life-threatening obstetric hemorrhage and the most common cause of peripartum hysterectomy aim of the work: to use tfc as a guide for 6% hes infusion of hypervolemic hemodilution in patients with placenta accreta to avoid fluid overload. objectives: * to calculate lus score at the end of infusion. * to evaluate tfc in k ohm-1. * to assess oxygen saturation, po2 and p/f ratio in abg. * to calculate the total infused volume in milliliters.


Eligibility criteria:
inclusion criteria: * female * 18-45 years old * asa i-ii exclusion criteria: * younger than 18 years, * asa \> or = iii * patients with respiratory, cardiac disease, cardiac arrhythmias, * body mass index above 40 kg/m2 * renal insufficiency, * sepsis, * hypovolemia denoted by ppv \> 13 detected after start of mechanical ventilation, * preoperative baseline lus score 10 or more, * tfc \> or = 26 k ohm-1, * patients with neck or chest lesions that impair the application of cardiometry electrodes

Keywords: thoracic fluid content lung ultrasound cesarean section placenta accreta colloid
neurobiologic, immunologic, and rheumatologic markers in youth with pans

Conditions: Pediatric Acute-Onset Neuropsychiatric Syndrome; Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections; PANS; PANDAS

Summary: this study is an investigation of the neurologic, immunologic, and rheumatologic markers of pediatric acute-onset neuropsychiatric syndrome (pans). pans is a condition characterized by the abrupt, dramatic onset of obsessive compulsive disorder (ocd) and/or eating restriction accompanied by equally abrupt and severe co-morbid neuropsychiatric symptoms, which include anxiety, emotional lability, depression, irritability, aggression, oppositionality, deterioration in school performance, behavioral (developmental) regression, sensory amplification, movement abnormalities, sleep disturbance, and urinary frequency. pans is thought to be caused by infection, inflammation, or alternate triggers that is associated with a brain response that leads to these symptoms. the purpose of this study is to examine specific neurologic, immunologic, rheumatologic, and genomic, components in children with the acute-onset of psychiatric symptoms. this research may begin to uncover a much larger story of autoimmune processes that are involved in psychiatric disorders of childhood. by better understanding the etiologic components of psychiatric phenomenon, future treatments may be better targeted to underlying causes.

the investigators will recruit 500 children, 1-18 years old at onset with pans/pandas. they will be treatment naive and within one month of onset/exacerbation. the 500 children with pans will be gender- and age-matched to 100 healthy children, to allow examination of immunologic, neurologic, genomic, and behavioral differences between these two groups of children.

Eligibility criteria:
inclusion criteria: * children with pans 1. age 1-18 at onset of pans 2. diagnosis of pans: abrupt onset of ocd or food restriction, and at least two of the following associated symptoms: frequent urination, worsening handwriting/cognition, inattention, anorexia, separation anxiety, oppositionality, irritability/rage outbursts, and emotional lability. 3. patients must live within 90 miles of stanford university and have a new onset of pans illness 4. patients must have an established pediatrician within 90 miles of stanford university for 3 years. * healthy controls 1. age 4-18 2. no psychiatric diagnosis exclusion criteria: * any neuropsychiatric illness that may obscure the clear diagnosis of pans

Keywords: pans pandas
correlation between elastic modulus of ultrasonic shear wave and tumor stromal component in pancreatic cancer

Conditions: Pancreatic Neoplasms

Summary: pancreatic cancer is a gastrointestinal tumor with a high degree of malignancy. currently, there are many first-line chemotherapy regimens in clinical practice, but the individual selection of chemotherapy regimens has not been unanimously recognized.this study is aimed at exploring the correlation between the two-dimensional shear wave elastography (2d - swe) parameters and pancreatic cancer stromal elements proportion through an ultrasound scan for resectable pancreatic cancer cases and postoperative pathological specimen analysis. then determine if the pancreatic cancer two-dimensional shear wave elastography can guide clinicians selecting chemotherapy scheme by predicting tumor stromal elements .these results are expected to provide an effective non-invasive diagnostic basis for individualized treatment of pancreatic cancer.


Eligibility criteria:
inclusion criteria 1. patients with resectable pancreatic cancer underwent ultrasound examination before surgery 2. conventional ultrasound can clearly show pancreatic space-occupying lesions and the elastic measurements show good images 3. the patient agrees to receive ultrasound elasticity examination and signs informed consent 4. all patients had no history of radiotherapy or chemotherapy before ultrasound examination 5. all clinical case data and auxiliary examination data are complete and accessible. exclusion criteria 1. ultrasound evaluation was not performed before ultrasound-guided needle biopsy 2. conventional ultrasound could not clearly show pancreatic space-occupying lesions or poor elastic measurement images 3. patients who refuse to accept examination or give up treatment 4. patients receiving neoadjuvant chemotherapy or radiotherapy before ultrasound examination 5. incomplete clinical data and auxiliary examination data.

Keywords: 2d-swe
mean arterial pressure (map) and renal perfusion: evaluation of critically ill patients with normal creatinine or reduced renal function

Conditions: Kidney Failure, Acute

Summary: the purpose of this study is to evaluate the renal perfusion depending on the map.


Eligibility criteria:
inclusion criteria: * over 18 years old * intensive care patient * treated with vasopressor * given informed consent * arterial infusion * a bladder catheter exclusion criteria: * anamneses of hypertension * neurological trauma * acute renal insufficiency other than prerenal or acute tubular necrosis etiology * hepatorenal syndrome * treated with diuretics * mechanical ventilation and unstable
the effect of sevoflurane and desflurane on clara cell protein on the lung

Conditions: Inhalation Anesthesia; Lung Injury

Summary: inhalation anesthesia; it means that the anesthetic drugs taken by the respiratory tract pass into the blood through the lung alveoli, reach the brain tissue, and create an anesthetic effect according to the density in the brain tissue. all inhalation anesthetics affect organ functions to varying degrees. clara cell has been shown to have cell regeneration, immunomodulatory, anti-inflammatory and antioxidant activity in the bronchial epithelium. it is also thought that some substances accumulated in the respiratory system participate in the detoxification. clara cell protein acts as a protein marker that indicates the severity of airway injuries after exposure to irritants. in this study, we planned to investigate the effect of inhalation anesthetics on clara cell protein in liver transplant donors who will undergo hepatectomy surgery.

inhalation anesthesia is still an important source of chemical hazard in the hospital environment due to its widespread use in operating rooms. factors affecting the presence of anesthetic gases in the environment; device leakage, ventilation, fresh gas flow, and operation of the air cleaning system. long-term exposure to anesthetic gases is known to adversely affect the health of employees in the operating room. clara cell plays a reliable role as a large bronchiolar progenitor cell that can contribute to cell regeneration in the bronchial epithelium. thus, it contributes to the protection of the normal epithelium of the distal conductive airways. additionally, it has been shown to have immunomodulatory, anti-inflammatory, and antioxidant activity. it is thought that some substances accumulated in the respiratory system participate in the detoxification. operations of patients undergoing hepatectomy usually take 4-6 hours. inhalation anesthetics are widely used during this surgery. in this study, we thought to show the effect of long-term inhalation anesthesia exposure by performing this surgery on patients in this group. in this study, we aimed to investigate the effect of sevoflurane and desflurane inhalation anesthetics on clara cell protein in liver transplant donors scheduled for hepatectomy surgery.

Eligibility criteria:
inclusion criteria: * living liver donors exclusion criteria: * smoking * under 18 years * over 65 years * patients who refused written informed consent forms

Keywords: sevoflurane desflurane clara cells protein